Literature DB >> 33622763

Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group.

Melyssa Aronson1,2, Chrystelle Colas3, Andrew Shuen4,5, Heather Hampel6, William D Foulkes7, Hagit Baris Feldman8,9, Yael Goldberg10,11, Martine Muleris12, Kami Wolfe Schneider13, Rose B McGee14, Kory Jasperson15, Arun Rangaswami16, Laurence Brugieres17,18, Uri Tabori19,20.   

Abstract

BACKGROUND: Constitutional mismatch repair deficiency syndrome (CMMRD) is the most aggressive cancer predisposition syndrome associated with multiorgan cancers, often presenting in childhood. There is variability in age and presentation of cancers and benign manifestations mimicking neurofibromatosis type 1. Genetic testing may not be informative and is complicated by pseudogenes associated with the most commonly associated gene, PMS2. To date, no diagnostic criteria exist. Since surveillance and immune-based therapies are available, establishing a CMMRD diagnosis is key to improve survival.
METHODS: In order to establish a robust diagnostic path, a multidisciplinary international working group, with representation from the two largest consortia (International Replication Repair Deficiency (IRRD) consortium and European Consortium Care for CMMRD (C4CMMRD)), was formed to establish diagnostic criteria based on expertise, literature review and consensus.
RESULTS: The working group established seven diagnostic criteria for the diagnosis of CMMRD, including four definitive criteria (strong evidence) and three likely diagnostic criteria (moderate evidence). All criteria warrant CMMRD surveillance. The criteria incorporate germline mismatch repair results, ancillary tests and clinical manifestation to determine a diagnosis. Hallmark cancers for CMMRD were defined by the working group after extensive literature review and consultation with the IRRD and C4CMMRD consortia.
CONCLUSIONS: This position paper summarises the evidence and rationale to provide specific guidelines for CMMRD diagnosis, which necessitates appropriate surveillance and treatment. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  diagnosis; gastrointestinal diseases; genetics; heredity; medical; medical oncology

Mesh:

Substances:

Year:  2021        PMID: 33622763     DOI: 10.1136/jmedgenet-2020-107627

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  10 in total

Review 1.  Improving protocols for whole-body magnetic resonance imaging: oncological and inflammatory applications.

Authors:  Mareen S Kraus; Ayat A Yousef; Sandra L Cote; Mary-Louise C Greer
Journal:  Pediatr Radiol       Date:  2022-08-19

2.  A Constitutional Mismatch Repair Deficiency Syndrome Presented With an Advanced Rectal Cancer in a Juvenile Female: A Case Report and Literature Review.

Authors:  Mohammed N AlAli; Abdulrahman H Zikry; Sulaiman A AlShammari; Mohammed Ayesh Zayed; Mohammed Alswayyed; Omar A AlObeed
Journal:  Cureus       Date:  2022-04-30

3.  Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.

Authors:  Ido Laish; Eitan Friedman; Gili Levi-Reznick; Inbal Kedar; Lior Katz; Zohar Levi; Naama Halpern; Shani Parnasa; Aasem Abu-Shatya; Elizabeth Half; Yael Goldberg
Journal:  Breast Cancer Res Treat       Date:  2021-06-04       Impact factor: 4.872

Review 4.  The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals.

Authors:  Cristina Carrato; Carolina Sanz; Ana María Muñoz-Mármol; Ignacio Blanco; Marta Pineda; Jesús Del Valle; Estela Dámaso; Manel Esteller; Eva Musulen
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

Review 5.  Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants.

Authors:  Hildegard Kehrer-Sawatzki; David N Cooper
Journal:  Hum Genet       Date:  2021-12-20       Impact factor: 4.132

6.  Case Report: Malignant Brain Tumors in Siblings With MSH6 Mutations.

Authors:  Di Wu; Qingshan Chen; Jian Chen
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

7.  Merged testing for colorectal cancer syndromes and re-evaluation of genetic variants improve diagnostic yield: Results from a nationwide prospective cohort.

Authors:  Sara Svensson; Theofanis Zagoras; Christos Aravidis; Marie Stenmark Askmalm; Erik Björck; Åke Borg; Ekaterina Kuchinskaya; Mef Nilbert; Margareta Nordling; Anna Rohlin; Gustav Silander; Kristina Lagerstedt-Robinson; Samuel Gebre-Medhin
Journal:  Genes Chromosomes Cancer       Date:  2022-05-02       Impact factor: 4.263

8.  Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.

Authors:  Inken Salewski; Julia Henne; Leonie Engster; Bjoern Schneider; Heiko Lemcke; Anna Skorska; Peggy Berlin; Larissa Henze; Christian Junghanss; Claudia Maletzki
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

9.  Mismatch repair deficiency in early-onset duodenal, ampullary, and pancreatic carcinomas is a strong indicator for a hereditary defect.

Authors:  Valentyna Kryklyva; Lodewijk Aa Brosens; Monica Aj Marijnissen-van Zanten; Marjolijn Jl Ligtenberg; Iris D Nagtegaal
Journal:  J Pathol Clin Res       Date:  2021-12-06

10.  Spectrum of DNA mismatch repair failures viewed through the lens of cancer genomics and implications for therapy.

Authors:  David Mas-Ponte; Marcel McCullough; Fran Supek
Journal:  Clin Sci (Lond)       Date:  2022-03-18       Impact factor: 6.124

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.